Exemestane - Pfizer

Drug Profile

Exemestane - Pfizer

Alternative Names: Aromasil; Aromasin; Aromasine; FCE 24304; Nikidess; PNU 155971

Latest Information Update: 04 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Emory University; German Breast Group; Pfizer
  • Class Androstadienes; Antineoplastics; Small molecules
  • Mechanism of Action Aromatase inhibitors; Estrogen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 12 Jun 2018 German Breast Group and Pfizer completes a phase III trial in Breast cancer (Male breast cancer, Combination therapy, Adjuvant therapy, Neoadjuvant therapy) in Germany (PO) (NCT01638247) (EudraCT2009-015122-11)
  • 22 Jan 2018 Pfizer completes a phase III trial in Breast cancer (Prevention) in USA, Canada, Puerto Rico and France (PO) (NCT00083174)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top